SCHEDULE: T. Rowe Price Discloses 2.8% Stake in Alkermes

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 4,664,563 shares of Alkermes PLC common stock, representing 2.8% of the class.

Summary

• T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, indicating its beneficial ownership of Alkermes PLC common stock.
• As of March 31, 2026, T. Rowe Price Associates, Inc. beneficially owns 4,664,563 shares of Alkermes PLC common stock.
• This holding represents 2.8% of the total class of securities.
• The filing specifies sole voting power for 4,650,687 shares and sole dispositive power for 4,664,563 shares.
• T. Rowe Price Associates, Inc. is classified as an investment adviser.
• The company certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of beneficial ownership by an institutional investor and does not contain operational or financial performance information about Alkermes PLC.

Positives

• T. Rowe Price Associates, Inc., a significant investment manager, holds a notable stake in Alkermes PLC, suggesting confidence in the company's prospects.
• The filing confirms T. Rowe Price's active management and oversight of its investments, with clear reporting of voting and dispositive power.

Negatives

• The filing does not contain any negative financial results or operational challenges for Alkermes PLC; it solely reports ownership.

Risks

• The filing does not explicitly mention any risks related to Alkermes PLC's operations or business. The risks are inherent to any investment, such as market fluctuations or company-specific performance.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Alkermes PLC's future performance. It is a disclosure of beneficial ownership.

Management Comments

• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• T. Rowe Price Associates, Inc. certifies that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by T. Rowe Price Associates, Inc. indicates a significant institutional investor's position in Alkermes PLC, a biopharmaceutical company. Such filings are common for large asset managers and reflect their investment strategies and holdings in the healthcare sector.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can be viewed positively by other shareholders as it may indicate confidence in the company's long-term value. However, it does not directly impact current share price or dividends.
• Management: The filing is a standard disclosure and does not directly impact Alkermes PLC's management team, other than acknowledging the presence of a large shareholder.
• Creditors: No direct impact on creditors is indicated by this ownership disclosure.

Next Steps

• No specific next steps for Alkermes PLC are mentioned in this filing. T. Rowe Price Associates, Inc. will continue to hold or manage its position as per its investment strategy.

Key Dates

Keywords

Alkermes PLC, Schedule 13G, T. Rowe Price Associates, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Securities Exchange Act